ITMCTR1900002376招募中1 期
Clinical study for the treatment of perimenopausal syndrome with the method of rank-side perforation
The Third Hospital of Shanxi College of Traditional Chinese Medicine ( Shanxi Provincial Acupuncture and Moxibustion Hospital)0 个研究点开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 性别
- Female
入选标准
- •(1) Comply with the diagnostic criteria for peri-menopausal syndrome in Western medicine;
- •(2) Comply with the diagnostic criteria for peri-menopausal syndrome in Chinese medicine;
- •(3) Baseline heating score = 4 points;
- •(4) Informed and agreed to participate in the study.
排除标准
- •(1) uterine and ovarian organic lesions; after ovarian, hysterectomy or local radiotherapy;
- •(2) Those who have a pregnancy or are pregnant in the near future;
- •(3) Currently receiving other therapies to treat the disease;
- •(4) Patients with severe liver and kidney dysfunction, infectious diseases, cardiovascular and cerebrovascular diseases, and mental illness;
- •(5) Those who have used sex hormones in the past 3 months.
研究者
相似试验
尚未招募
1 期
Clinical study on the treatment of Perimenopausal Insomnia with Yishen Pinggan DecoctioITMCTR2000003635Shanghai Municipal Hospital Traditional Chinese Medicine
招募中
不适用
Clinical study on treatment of Postmenopausal Syndrome after operation of gynecologic malignant tumor with acupuncture and medicinePostmenopausal SyndromeITMCTR2100004484Zhejiang Provincial People's Hospital
进行中（未招募）
不适用
First- Line Treatment of Postmenopausal Patients with Endocrine Responsive Metastatic Breast Cancer. A Randomized, Multicenter Study Comparing Letrozole Combined with Standard Chemotherapy Vs Letrozole Single Agent. The CELER (= CEsar LEtrozole Randomized phase III) Study - CELER Studyhormone-receptor-positive metastatic breast cancerMedDRA version: 8.0Level: PTClassification code 10055113EUCTR2005-001701-26-ATCESAR Central European Society for550
进行中（未招募）
不适用
First- Line Treatment of Postmenopausal Patients with Endocrine Responsive Metastatic Breast Cancer. A Randomized, Multicenter Study Comparing Letrozole Combined with Standard Chemotherapy Vs Letrozole Single Agent. The CELER (= CEsar LEtrozole Randomized phase III) Study - CELER StudyEUCTR2005-001701-26-HUCESAR Central European Society for550
进行中（未招募）
不适用
First- Line Treatment of Postmenopausal Patients with Endocrine Responsive Metastatic Breast Cancer. A Randomized, Multicenter Study Comparing Letrozole Combined with Standard Chemotherapy Vs Letrozole Single Agent. The CELER (= CEsar LEtrozole Randomized phase III) Study - CELER Studyhormone-receptor-positive metastatic breast cancerMedDRA version: 8.0Level: PTClassification code 10055113EUCTR2005-001701-26-SICESAR Central European Society for550